Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Rank in Stocks #25854
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Share Price
$15.31
Last synced: 2024-02-29
Market Cap
$45.70M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Icosavax, Inc. (ICVX)

Category

P/S ratio for Icosavax, Inc. (ICVX)
P/S ratio as of 2026 TTM: 0
According to Icosavax, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Icosavax, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
11.28 -
US